Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols

Hemodialysis International

Volumn 16, Issue 2, 2012, Pages 188-197

  Chertow, Glenn M ^a   Lu, Z John ^b   Xu, Xiao ^c   Knight, Tyler G ^c   Goodman, William G ^b   Bushinsky, David A ^d   Block, Geoffrey A ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c 206 Carnegie Center   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e Denver Nephrology   (United States)

Author keywords

Hemodialysis; Outcomes; Secondary hyperparathyroidism; Symptoms

Indexed keywords

CINACALCET; PARATHYROID HORMONE; PARICALCITOL;

ARTHRALGIA; ARTICLE; BONE PAIN; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRY SKIN; FEMALE; HEMODIALYSIS; HUMAN; JOINT STIFFNESS; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; MYALGIA; PRURITUS; QUESTIONNAIRE; SECONDARY HYPERPARATHYROIDISM;

COHORT STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; SELF REPORT; TREATMENT OUTCOME; VITAMIN D;

EID: 84859560396     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00642.x     Document Type: Article

References (33)

1. de Boer IH, Gorodetskaya I, Young B, etal. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, racedependent and associated with cardiovascular disease. J Am Soc Nephrol. 2002; 13:2762-2769.
2. Levin A, Bakris GL, Molitch M, etal. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71:31-38.
3. Hörl WH. The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes. Nephrol Dial Transplant. 2004; 19(Suppl 5):V2-V8.
4. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant. 2003; 18(Suppl 3):iii2-iii8.
5. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007; 13:397-411.
6. Mustonen AO, Kiuru MJ, Stahls A, Bohling T, Kivioja A, Koskinen SK. Radicular lower extremity pain as the first symptom of primary hyperparathyroidism. Skeletal Radiol. 2004; 33:467-472.
7. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritis-new perspectives and insights from recent trials. Neph Dial Transplant. 2002; 17:1558-1563.
8. Merkus MP, Jager KJ, Dekker FW, etal. Physical symptoms and quality of life in patients on chronic dialysis: Results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant. 1999; 14:1163-1170.
9. Nakai S, Shinzato T, Sanaka T, etal. An overview of dialysis treatment in Japan (as of Dec. 31, 1999). J Jpn Soc Dial Ther. 2001; 34:1121-1147.
10. Curtin RB, Bultman DC, Thomas-Hawkins C, etal. Hemodialysis patients'symptom experiences: Effects on physical and mental functioning. Neph Nursing J. 2002; 29:562-574.
11. Paiseka JL, Parsons LL. A prospective surgical outcome study assessing the impact of parathyroidectomy on symptoms in patients with secondary and tertiary hyperparathyroidism. Surgery. 2000; 128:531-539.
12. Evenepoel P. Calcimimetics in chronic kidney disease: Evidence, opportunities and challenges. Kidney Int. 2008; 74:265-275.
13. Barrett BJ, Vavasour HM, Major A, Parfrey PS. Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron. 1990; 55:10-15.
14. Cengiz K, Ozkan A. Depression and secondary hyperparathyroidism in chronic renal failure. Nephron. 1998; 79:508-509.
15. Cho YL, Lui HN, Huang TP, Tarng DC. Uremic pruritus: Roles of parathyroid hormone and substance P. J Am Acad Dermatol. 1997; 36:538-543.
16. Cunningham J, Floege J, London G, Rodriguez M, Shanahan CM. Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus. 2008; 1(Suppl 1): i29-i35.
17. Block GA, Martin KJ, de Francisco AL, etal. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350:1516-1525.
18. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68:1793-1800.
19. Block GA, Zeig S, Sugihara J, etal. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008; 23:2311-2318.
20. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994; 3:329-338.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: Conceptual framework and item selection. Med Care. 1992; 30:473-483.
22. Ware JE, Snow KK, Kosinski M, etal. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
23. Pisoni RL, Wilstrom B, Elder SJ, etal. Pruritus in hemodialysis patients: Internal results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006; 21:3495-3505.
24. Meyer KB, Espindle DM, DeGiacomo JM, Jenuleson CS, Kurtin PS, Davies AR. Monitoring dialysis patients' health status. Am J Kidney Dis. 1994; 24:267-279.
25. Fujisawa M, Ichikawa Y, Yoshiya K, etal. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology. 2000; 56:201-206.
26. Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S. Self-assessed physical and mental functioning of hemodialysis patients. Nephrol Dial Transplant. 2001; 16:1387-1394.
27. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The association between mental health, physical function, and hemodialysis mortality. Kidney Int. 2003; 63:1843-1851.
28. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997; 30:606-620.
29. Chiou FF, Lee CH, Chen JB. General weakness as an indication for parathyroid surgery in patients with secondary hyperparathyroidism. Arch Surg. 1999; 134:1108-1111.
30. Chiou FF, Lee CH, Lee CT. Muscle force and bone mineral density after parathyroidectomy and subcutaneous auto-transplantation for secondary hyperparathyroidism. World J Surg. 1999; 23:452-456.
31. Edgell ET, Coons SJ, Carter WB, etal. A review of health-related quality of life assessment in end-stage renal disease. Clin Ther. 1996; 18:887-938.
32. Neonakis E, Wheeler MH, Krishnan H, etal. Results of surgical treatment of renal hyperparathyroidism. Arch Surg. 1995; 130:643-648.
33. Chertow GM, Pupim LB, Block GA, etal. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol. 2007; 2:898-905.